Spinifex to be acquired by Novartis

Australian pain drug innovation company sold to Novartis for US$200m plus milestone payments

02-Jul-2015 - Spinifex Pharmaceuticals, Inc. and its Australian subsidiary Spinifex Pharmaceuticals Pty Ltd, a company focused on the development of new drugs for the treatment of chronic pain, announced agreement to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 ...

Spinifex Pharmaceuticals Appoints Chief Medical Officer

05-Jun-2014 - Spinifex Pharmaceuticals announced that it has appointed Dr Ronald Marcus as Chief Medical Officer. Dr Marcus will be responsible for driving the development of Spinifex’s lead candidate EMA401 and the Company’s pre-clinical pipeline. He takes up his position immediately. Dr Marcus has more than ...

Spinifex Announces Positive Phase 2 Results for EMA401 in Postherpetic Neuralgia

Trial Meets Primary Endpoint: Reduction in Pain

29-Aug-2012 - Spinifex Pharmaceuticals announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all ...

Spinifex Appoints Declan Doogan as Non-Executive Chairman

13-Dec-2011 - Spinifex Pharmaceuticals announces the appointment of Dr Declan Doogan as Non-Executive Chairman. Dr Doogan brings to Spinifex more than 30 years’ experience of the global pharmaceuticals industry including more than 20 years with Pfizer.Dr Doogan is currently Chief Medical Officer of Amarin ...

Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Postherpetic Neuralgia

20-Sep-2011 - Spinifex Pharmaceuticals, an Australian pain drug development company, announced the first patients have been treated in its Phase 2 clinical trial of EMA401 in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing ...